Is remdesivir authorized for anyone hospitalized with COVID-19?
By Esther Tsvayg
Copy link
Copy featured image
YES
In August the Food and Drug Administration broadened its earlier emergency-use authorization of remdesivir, expanding its scope to include treatment of all hospitalized adult or pediatric patients with suspected or laboratory-confirmed cases of COVID-19, "irrespective of their severity of the disease."
Complete understanding of the drug's benefits continues to evolve. Three clinical trials so far have produced varying results.
This fact brief is responsive to conversations such as this one.
Sources
ABOUT THE CONTRIBUTOR
Between 2020 and 2022, under close editorial supervision, Gigafact contracted a group of freelance writers and editors to test the concepts for fact briefs and provide inputs to our software development process. We call this effort Gigafact Foundry. Over the course of these two years, Gigafact Foundry writers published over 1500 fact briefs in response to claims they found online. Their important work forms the basis of Gigafact formats and editorial guidelines, and is available to the public on Gigafact.org. Readers should be aware that while there is still a lot of relevant information to be found, not all fact briefs produced by Gigafact Foundry reflect Gigafact's current methods and standards for fact briefs. If you come across any that you feel are out of date and need to be looked at with fresh eyes, don't hesitate to contact us at support@gigafact.org.
